

IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A multilayer dosage form ~~composed~~ comprised of

- a) a neutral core,
- b) an inner coating of a methacrylate copolymer
- c) an outer coating of a copolymer which is ~~composed~~ comprised of 40 to 95%

by weight free-radical polymerized C₁- to C₄-alkyl esters of acrylic or of methacrylic acid and 5 to 60% by weight (meth)acrylate monomers having an anionic group in the alkyl radical,

wherein ~~characterized in that~~

the inner coating consists substantially of a methacrylate copolymer which is ~~composed~~ comprised of at least 90% by weight of (meth)acrylate monomers having neutral radicals, has a minimum film-forming temperature as specified in DIN 53 787 not exceeding 30°C, and comprises the pharmaceutical active substance in bound form.

Claim 2 (Currently Amended): The multilayer dosage form as claimed in claim 1, ~~characterized in that~~ wherein the methacrylate copolymer of the inner coating is polymerized from 25-35% by weight methyl methacrylate, 75 to 65% by weight ethyl acrylate and, where appropriate, up to 10% by weight other vinylically polymerizable monomers, ~~in particular (meth)acrylate monomers with polar or ionic radicals, where~~ wherein the proportionate amounts add up to 100% by weight.

Claim 3 (Currently Amended): The multilayer dosage form as claimed in claim 1, wherein ~~claim 1 or 2, characterized in that~~ the active substance/polymer ratio of the inner layer is from 20:1 to 1:20.

Claim 4 (Currently Amended): The multilayer dosage form as claimed in claim 1, ~~wherein one or more of claims 1 to 3, characterized in that~~ the outer coating consists substantially of a (meth)acrylate copolymer of 40 to 60% by weight methacrylic acid and 60 to 40% by weight methyl methacrylate or 60 to 40% by weight ethyl acrylate.

Claim 5 (Currently Amended): The multilayer dosage form as claimed in claim 1, ~~wherein one or more of claims 1 to 3, characterized in that~~ the outer coating consists substantially of a (meth)acrylate copolymer of 20 to 40% by weight methacrylic acid and 80 to 60% by weight methyl methacrylate.

Claim 6 (Currently Amended): The multilayer dosage form as claimed in claim 1, ~~wherein one or more of claims 1 to 3, characterized in that~~ the outer coating consists substantially of a (meth)acrylate copolymer of 20 to 34% by weight methacrylic acid and/or acrylic acid, 20 to 69% by weight methyl acrylate, 0 to 40% by weight ethyl acrylate and, where appropriate, 0 to 10% by weight further vinylically copolymerizable monomers, ~~with the proviso that~~ wherein the glass transition temperature of the copolymer as specified in ISO 11357-2, subsection 3.3.3, does not exceed 60°C.

Claim 7 (Currently Amended): The multilayer dosage form as claimed in claim 1, ~~wherein one or more of claims 1 to 3, characterized in that~~ the outer coating consists substantially of a (meth)acrylate copolymer consisting of 10 to 30% by weight methyl methacrylate, 50 to 70% by weight methyl acrylate and 5 to 15% by weight methacrylic acid.

Claim 8 (Currently Amended): The multilayer dosage form as claimed in claim 1, ~~wherein said multilayer dosage form one or more of claims 1 to 7, characterized in that it~~

comprises an active substance from the active substance classes of aminosalicylates, of sulfonamides or of glucocorticoids.

Claim 9 (Currently Amended): The multilayer dosage form as claimed in claim 8, ~~characterized in that it~~ wherein said multilayer dosage form comprises the active substance 5-aminosalicylic acid, olsalazine, sulfalazine, prednisone, prednisolone or budesonide.

Claim 10 (Currently Amended): The multilayer dosage form as claimed in claim 1, ~~wherein said multilayer dosage form one or more of claims 1 to 7, characterized in that it~~ comprises an active substance from the active substance classes of enzymes, peptide hormones, immunomodulatory proteins, antigens, antibodies or of oligonucleotides.

Claim 11 (Currently Amended): The multilayer dosage form as claimed in claim 10, ~~characterized in that it~~ wherein said multilayer dosage form comprises the active substance pancreatin, insulin, human growth hormone (hGH), carbaplatin, intron A, calcitonin, cromalyn, interferons, calcitonin, granulocyte colony stimulating factor (G-CSF), interleukin, parathyroid hormones, glucagon, pro-somatostatin, somatostatin, detirelix, cetrorelix, vasopressin, 1-deaminocysteine-8-D-arginine-vasopressin, leuprolide acetate or an antigen which has been isolated from one or more grasses or one or more other plants ~~such as, for example, rye, wheat, barley, oats, bermuda grass, horsetail, sycamore, elm, oak, plane tree, poplar, cedar, horsetail, thistles.~~

Claim 12 (Currently Amended): The multilayer dosage form as claimed in claim 1, ~~wherein one or more of claims 1 to 6, characterized in that~~ the values for the percentage release of active substance in a hypotonic and an isotonic release medium based on phosphate

Docket No. 267336US0PCT
Preliminary Amendment

buffer pH 6.8 do not differ from one another at any time in the period from 1 to 5 hours by more than 10%.